Riskpilot← Back to searchSign inGet full accessCHR. OLESEN SYNTHESIS A/S
A/SActiveCVR 33964870Kanalholmen 8-12Manufacture of basic pharmaceutical products · NACE 2110Est. 201193 employees
Revenue 2025
DKK 7M
-34% vs 2024
EBITDA margin
-14.6%
-125% vs 2024
Equity ratio
-38.9%
Financial strength
Net profit 2025
DKK -2,3M
-131% vs 2024
| Revenue | DKK 7M | -34% |
| EBITDA | DKK -1M | -125% |
| Net profit | DKK -2,3M | -131% |
| Total assets | DKK 24,4M | +11% |
| Equity | DKK -9,5M | -32% |
| Employees | 93 | — |
Legal name
CHR. OLESEN SYNTHESIS A/S
CVR number
33964870
Legal form
Aktieselskab
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
17. oktober 2011
Share capital
DKK 538.358
Employees
93 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, ét bestyrelsesmedlem i forening med en direktør eller én direktør.
Company purpose
Selskabets formål er produktion af aktive pharmaceutiske ingredienser samt hermed beslægtet virksomhed.
Address
Kanalholmen 8-12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -47 | 3.644 | 5.423 | 10.568 | 6.959 |
| Staff expenses | -3.891 | -4.705 | -5.482 | -6.548 | -7.974 |
| EBITDA | -3.937 | -1.060 | -58 | 4.020 | -1.015 |
| Depreciation & amort. | -557 | -563 | -616 | -663 | -785 |
| EBIT | -4.494 | -1.623 | -675 | 3.357 | -1.800 |
| Net financials | -62 | -565 | -848 | -977 | -979 |
| Profit before tax | -4.556 | -2.189 | -1.522 | 2.380 | -2.779 |
| Tax | -0 | -0 | -0 | -5.012 | -480 |
| Net profit | -4.556 | -2.189 | -1.522 | 7.392 | -2.299 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 10.496 | 12.507 | 14.923 | 22.006 | 24.386 |
| Equity | -10.872 | -13.060 | -14.583 | -7.191 | -9.490 |
| Long-term debt | 16.814 | 21.269 | 22.762 | 23.117 | 24.561 |
| Short-term debt | 4.554 | 4.299 | 6.743 | 6.080 | 9.315 |
| Total debt | 21.368 | 25.567 | 29.505 | 29.197 | 33.876 |
EBITDA margin
-14.6%
This company
15.8%
Market median
-192% vs market
20212025
Equity ratio
-38.9%
This company
38.2%
Market median
-202% vs market
20212025
Return on equity
-229904600.0%
This company
18.4%
Market median
-1249481622% vs market
20212025
Net profit margin
-33.0%
This company
8.1%
Market median
-507% vs market
20212025
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20212025
Debt / equity
3.57×
This company
0.62×
Market median
-476% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TM Chief Executive Officer | Chief Executive Officer | 2018 |
| Former (2) | ||
SA Management | Management | 2011 – 2012 |
TA Management | Management | 2012 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2011 | |
| Board of Directors | 2015 | |
| Board of Directors | 2015 | |
| Former (2) | ||
| Board of Directors | 2011 – 2012 | |
| Board of Directors | 2016 – 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2015 | |
| Individual | 33.33–49.99% | 33.33–49.99% | 2015 | |
| Individual | 5–9.99% | 5–9.99% | 2015 | |
| Company | 25–33.32% | 25–33.32% | 2013 | |
| Company | 15–19.99% | 15–19.99% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Chr. Olesen Holding II A/SCHR. OLESEN HOLDING A/SCHR. OLESEN A/S
CHR. OLESEN SYNTHESIS A/S (this company)Board members of CHR. OLESEN SYNTHESIS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svend Aage Johansen | Management | 0 companies |
| Terje Aarbogh | Management | 0 companies |
| Thomas Michael Moestrup | Chief Executive Officer | 0 companies |
| Mads Christian Olesen | Chairman | 0 companies |
| Tibor Simon | Board of Directors | 0 companies |
| Allan Ardensø | Board of Directors | 0 companies |
| James Charles Gale | Board of Directors | 0 companies |
| Jørgen Damsbo Andersen | Board of Directors | 0 companies |